Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.
Aditya Bardia, Cesar Augusto Santa-Maria, Lisa K. Jacobs, Ashley Cimino‐Mathews, Peng Huang, Stuart D. Russell, Melissa Camp, Mehran Habibi, Julie R. Lange, Stacie C. Jeter, Penny Powers, Shannon A. Slater, Edward Gabrielson, Michael A. Carducci, Gregg L. Friedman, Vered Stearns (2013). Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. , 31(15_suppl), DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.tps1144.
Article164 days agoSerial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
Stuart D. Russell, Alexander R. Lyon, Daniel J. Lenihan, Philippe Moreau, Douglas Joshua, Wee Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Façon, Heinz Ludwig, Luděk Pour, Rubén Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaïdano, Vesselina Goranova‐Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Meletios A Dimopoulos (2015). Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4250.4250.
Article14 days ago